

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Amended): A method of enhancing an immune response to an antigen in a mammal comprising administering lymphocyte conditioned media in combination with a vaccine of said antigen to said mammal.
2. (Original): The method of Claim 1, wherein said lymphocyte conditioned media is derived from naïve T cells cultured with antiCD3/CD28-coated beads.
3. (Original): The method of Claim 1, wherein said antigen is HIV-1 or HIV-2.
4. (Original): The method of Claim 1, wherein said antigen is hepatitis-B.
5. (Original): The method of Claim 1, wherein said antigen is tetanus toxoid.
6. (Original): The method of Claim 1, wherein said antigen is prostate-specific antigen.
7. (Original): The method of Claim 1, wherein said antigen is hepatitis-A.
8. (Original): The method of Claim 1, wherein said antigen is diptheria.
9. (Original): The method of Claim 1, wherein the dosage of said lymphocyte conditioned medium is about 10 µg to about 500 µg.
10. (Original): The method of Claim 1, wherein said administration is selected from the group consisting of intracutaneous, subcutaneous and intramuscular injection and combinations thereof.
11. (Original): The method of Claim 1, wherein said administration is selected from the group consisting of weekly, biweekly, monthly, and yearly and combinations thereof.
12. (Previously Presented): A vaccine adjuvant composition for stimulation of an immune response in a host animal comprising
supernatant derived from activated human lymphocytes cells cultured with growth media.

13. (Previously Presented): The composition of Claim 12, wherein said activation of said cells is effected with antibodies to CD3/CD28.

14. (Previously Presented): A vaccine adjuvant composition for stimulation of an immune response in a host animal comprising processed activated human lymphocytes cells cultured with growth media.

15. (Previously Presented): The composition of Claim 14, wherein said activation of said cells is effected with antibodies to CD3/CD28.